ArticleJournal of fish diseases2026
Screening and Application of Novel DNA Aptamers for Targeting Tilapia Lake Virus-Infected Cells.
Article in Journal of fish diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tilapia Lake Virus (TiLV) is an emerging pathogen that poses a significant threat to global tilapia aquaculture, leading to substantial economic losses. The development of rapid, sensitive, and specific diagnostic methods is crucial for disease control and prevention. In this study, TiLV-infected tilapia brain cell line (TiB cells) was used as the target for screening specific aptamers via the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) technique. The affinity, specificity, stability, cytotoxicity, and antiviral activity of the obtained aptamers were systematically analysed through flow cytometry, confocal laser scanning microscopy, real-time quantitative PCR, and cell viability assays. This study successfully screened and obtained two aptamers, LH-1 and LH-2. Both aptamers specifically recognize and bind to TiLV-infected TiB cells while showing no cross-reactivity with normal cells or cells infected with other viruses. Their secondary structures exhibit typical stem-loop configurations, with dissociation constants (Kd) reaching nanomolar levels at 506.9 nM and 326.4 nM, respectively, and they demonstrate no cytotoxicity toward host cells. Aptamer LH-2 is capable of detecting as few as 1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.